Autolus Therapeutics (AUTL): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
5 concentrated managers hold it with a median weight of 0.2%.
Who owns Autolus Therapeutics?
Autolus Therapeutics trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): MAK Capital Fund, 12.6% (13G/A filed May 15, 2026), Syncona Portfolio, 10.8% (13G/A filed May 7, 2025), Armistice Capital, 5.6% (13G/A filed Aug 14, 2026) and Renata Kellnerova, 5.6% (13D/A filed Aug 28, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were MAK Capital One (33.6 million ADRs), Blackstone (20.5 million ADRs) and Syncona Portfolio (16.6 million ADRs).
Which institutions hold the most Autolus Therapeutics shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. MAK Capital One: 33.6 million ADRs
- 2. Blackstone: 20.5 million ADRs
- 3. Syncona Portfolio: 16.6 million ADRs
- 4. Armistice Capital: 15.0 million ADRs
- 5. Tetragon Partners GP: 9.5 million ADRs
- 6. Schroder Investment Management Group: 7.8 million ADRs
- 7. Frazier Life Sciences Management: 4.4 million ADRs
- 8. BNP PARIBAS ASSET MANAGEMENT Holding: 3.4 million ADRs
- 9. Laurion Capital Management: 3.3 million ADRs
- 10. Renaissance Technologies: 2.0 million ADRs
Sources:13G/A by MAK Capital Fund (May 15, 2026) ↗13G/A by Syncona Portfolio (May 7, 2025) ↗13G/A by Armistice Capital (Aug 14, 2026) ↗13D/A by Renata Kellnerova (Aug 28, 2026) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Autolus Therapeutics revenue
Autolus Therapeutics reported annual revenue of $75.4 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Change in managers (5 → 5): 0 opened · 0 exited = 0
Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
The set of concentrated managers changed between quarters: with the set as it was then, 6 held it last quarter (the chart point); with today's set, 5 (the base for the change).
Concentrated managers holding it
- MAK Capital One$53.8M7.5%
- Tetragon Partners GP$15.2M2.5%
- Frazier Life Sciences Management$7.1M0.2%
- Privium Fund Management B.V$581K0.1%
- DAFNA Capital Management$287K0.1%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of AUTL (all 13F filers)
- MAK Capital Oneconcentrated33.6 MInvestment firm · 12.63% of the company0
- Blackstone20.5 MPrivate equity or venture capital · 7.70% of the company0
- Syncona Portfolio16.6 MSingle-position portfolio · 6.25% of the company0
- Armistice Capital15.0 MType not verified · 5.64% of the company−800 K
- Tetragon Partners GPconcentrated9.5 MType not verified · 3.57% of the company0
- Schroder Investment Management Group7.8 MInvestment firm · 2.94% of the company−1.7 M
- Frazier Life Sciences Managementconcentrated4.4 MInvestment firm · 1.67% of the company0
- BNP PARIBAS ASSET MANAGEMENT Holding3.4 MInvestment firm · 1.26% of the company0
- Laurion Capital Management3.3 MType not verified · 1.25% of the company0
- Renaissance Technologies2.0 MQuant or multi-manager · 0.75% of the company−315 K
- MAK Capital Oneconcentrated
- Shares
- 33.6 M
- Change
- 0
- % of the company
- 12.63%
See more
- Type
- Investment firm
- Value
- $53.8M
- Shares
- 20.5 M
- Change
- 0
- % of the company
- 7.70%
See more
- Type
- Private equity or venture capital
- Value
- $32.8M
- Syncona Portfolio
- Shares
- 16.6 M
- Change
- 0
- % of the company
- 6.25%
See more
- Type
- Single-position portfolio
- Value
- $26.6M
- Shares
- 15.0 M
- Change
- −800 K
- % of the company
- 5.64%
See more
- Type
- Type not verified
- Value
- $24.0M
- Tetragon Partners GPconcentrated
- Shares
- 9.5 M
- Change
- 0
- % of the company
- 3.57%
See more
- Type
- Type not verified
- Value
- $15.2M
- Shares
- 7.8 M
- Change
- −1.7 M
- % of the company
- 2.94%
See more
- Type
- Investment firm
- Value
- $12.9M
- Frazier Life Sciences Managementconcentrated
- Shares
- 4.4 M
- Change
- 0
- % of the company
- 1.67%
See more
- Type
- Investment firm
- Value
- $7.1M
- Shares
- 3.4 M
- Change
- 0
- % of the company
- 1.26%
See more
- Type
- Investment firm
- Value
- $5.4M
- Shares
- 3.3 M
- Change
- 0
- % of the company
- 1.25%
See more
- Type
- Type not verified
- Value
- $5.3M
- Shares
- 2.0 M
- Change
- −315 K
- % of the company
- 0.75%
See more
- Type
- Quant or multi-manager
- Value
- $3.2M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- —
- Revenue (TTM)
- $117M
- Revenue growth
- 292.2%
- Net income (TTM)
- $-280M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- $-233M
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Shares outstanding: buybacks and dilution
2025: 266.1 M
- 1 year
- +4.3%
- 3 years
- +24.5%
- 5 years
- +2.0%
- Buybacks (FY 2025)
- no data
- Share issuance
- $0
- Stock-based compensation
- $14.4M19.2% of revenue
- Dividends paid
- no data
From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Interest coverage (operating income ÷ interest)
- −7.4 timesnegative operating income
- Debt due within 12 months
- no data
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- Renata Kellnerova5.6%13D · amendmentfiling ↗Event: Aug 27, 2026 · filed: Aug 28, 2026
- Armistice Capital5.64%13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Aug 14, 2026
- MAK Capital Fund12.6%13G · amendmentfiling ↗Event: Mar 31, 2026 · filed: May 15, 2026
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Exit or restructuring costs (Item 2.05)
«Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction»
Change of auditor (Item 4.01)
Unregistered sale of equity securities (Item 3.02)
Change in directors or officers (Item 5.02)
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers
- Crinetics PharmaceuticalsCRNX · 5 managers
- IncyteINCY · 5 managers
- Summit TherapeuticsSMMT · 5 managers
- Achieve Life SciencesACHV · 6 managers